The issue will consist of the issuance of fresh equity shares worth up to Rs 331.60 crore and an offer for sale (OFS) of Rs 500 crore by promoters and existing shareholders
The revenues and profits derived from the new subsidiary will be consolidated in the parent company
Acetaminophen extended-release tablets 650 mg is bioequivalent of the reference listed drug Tylenol
The company will manufacture the products at its US FDA approved oral dosage facility at Goa in India
It is part of the company’s pain/analgesics portfolio of OTC products
Proceeds from the IPO will be used for the expansion of the Dehradun facility.
The first six batches are being shipped to the Gamaleya Center, Moscow for the quality approval
According to IQVIA sales data for the 12 month period ending April 2021, the Ofev Capsules, 100 mg and 150 mg market achieved annual sales of approximately US $1.6 billion
ICICI Securities expects Hemmo to grow its revenue at a CAGR of 30.0% over FY21E-FY23E
PEL will explore the PLI scheme and apply if its beneficial.
Subscribe To Our Newsletter & Stay Updated
